Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells

Patent metadata

Field	Value
Publication number	US-10874753-B2
Application number	US-201515514138-A
Country	US
Kind code	B2
Filing date	Sep 25, 2015
Priority date	Sep 26, 2014
Publication date	Dec 29, 2020
Grant date	Dec 29, 2020

Abstract

This invention relates new radiopharmaceutical conjugates for use in improved methods of diagnosis and treatment of cancer. The radiopharmaceutical conjugate comprises, in sequence: a metabolite that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to a linker capable of binding with an EPR agent in vitro or in vivo; or a chelating agent capable of containing a radionuclide, bound to a metabolite that targets tumour cells, bound to a linker capable of binding with an EPR agent in vitro or in vivo. The radiopharmaceutical conjugates of the present invention provide active and passive targeted radio nuclide delivery systems that can help to improve the biodistribution and pharmacological toxicity of the radiopharmaceuticals used for the diagnosis and therapy of cancer.

First claim

The invention claimed is:

1. A molecule comprising a metabolite that targets tumour cells, a chelating agent capable of containing a radionuclide, and a cleavable linker capable of binding with an EPR agent, or a cleavable linker bound to an EPR agent,
wherein the molecule is a linear molecule comprising, in sequence:
a metabolite that is less than 1000 Da is size and that targets tumour cells, bound to a chelating agent capable of containing a radionuclide, bound to
a) a cleavable linker capable of binding with an EPR agent that is greater than 40 kDa in size or
b) a cleavable linker bound to an EPR agent that is greater than 40 kDa in size,

wherein the cleavable linker contains a cleavable bond that is cleaved in vivo within a tumour environment.

2. The molecule claimed in claim 1 , wherein the cleavable bond cleaved in vivo within a tumour environment by a pH of less than 7, by glutathione, or where there is up-regulation of enzymes.

3. The molecule claimed in claim 1 , wherein the cleavable linker is bound to the EPR agent.

4. The molecule claimed in claim 1 , wherein the cleavable linker comprises a carbon chain of 4 to 20 carbon atoms.

5. The molecule claimed in claim 4 , wherein the cleavable linker comprises a carbon chain of 8 to 15 carbon atoms.

6. The molecule claimed in claim 2 , wherein the cleavable linker contains a hydrazone bond, a disulfide bond, or enzymatically cleavable peptide sequences.

7. The molecule claimed in claim 3 , wherein the EPR agent is selected from polymeric nanoparticles, polymeric micelles, dendrimers, liposomes, viral nanoparticles, carbon nanoparticles, and proteins that accumulate in a tumour in vivo due to the Enhanced Permeability and Retention (EPR) effect.

8. The molecule claimed in claim 7 , wherein the EPR agent is a synthetic polymer that is biodegradable, a synthetic polymer that is biocompatible but not biodegradable, or a natural polymer.

9. The molecule claimed in claim 8 , wherein the biodegradable synthetic polymer is polyglutamate (PG), polylactide (PLA) or poly(D,L-lactide-co-glycolide)(PLGA).

10. The molecule claimed in claim 8 , wherein the polymer that is biocompatible but not biodegradable is Polyethylene glycol (PEG) or N-(2-hydroxypropyl) methylacrylamide (HMPA).

11. The molecule claimed in claim 8 , wherein the natural polymer is albumin, chitosan or heparin.

12. The molecule claimed in claim 1 , wherein the metabolite that targets tumour cells is 100 to 700 Da in size.

13. The molecule claimed in claim 12 , wherein the metabolite that targets tumour cells is folate, mannose, glucose or galactose.

14. The molecule claimed in claim 1 , wherein the chelating agent is a cyclic or acyclic bifunctional chelating agent (BFCA) which is able to complex a radioisotope.

15. The molecule claimed in claim 14 , wherein the chelating agent is a cyclic chelator selected from: 1,4,7-Triazacyclononane (TACN); 1,4,7-triazacyclononane-triacetic acid (NOTA); 1,4,7-triazacyclononane-N-succinic acid-N′,N″-diacetic acid (NOTASA); 1,4,7-triazacyclononane-N-glutamic acid-N′,N″-diacetic acid (NODAGA); 1,4,7-triazacyclononane-N,N′,N″-tris (methylenephosphonic) (NOTP); 1,4,7,10-tetraazacyclododecane ([12]aneN4) (cyclen); 1,4,7,10-tetraazacyclotridecane ([13]aneN4); 1,4,7,11-tetraazacyclotetradecane (iso-cyclam); 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA); 2-(1,4,7,10-tetraazacyclododecan-1-yl)acetate (DO1A); 2,2′-(1,4,7,10-tetraazacyclododecane-1,7-diyl) diacetic acid (DO2A); 2,2′,2″-(1,4,7,10-tetraazacyclododecane-1,4,7-triyl) triacetic acid (DO3A); 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra(methanephosphonic acid) (DOTP); 1,4,7,10-tetraazacyclododecane-1,7-di(methanephosphonic acid) (DO2P); 1,4,7,10-tetraazacyclododecane-1,4,7-tri(methanephosphonic acid) (DO3P); 1,4,7,10-tetraazacyclo-decane-1-glutamic acid-4,7,10-triacetic acid (DOTAGA); 1,4,7,10-tetraazacyclodecane-1-succinic acid-4,7,10-triacetic acid (DOTASA); 1,4,8,11-tetraazacyclotetradecane ([14]aneN4) (cyclam); 1,4,8,12-tetraazacyclopentadecane ([15]aneN4); 1,5,9,13-tetraazacyclohexadecane ([16]aneN4); 1,4-ethano-1,4,8,11-tetraazacyclo-tetradecane (et-cyclam); 1,4,8,11-15-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA); 2-(1,4,8,11-tetraazacyclotetradecane-1-yl) acetic acid (TE1A); 2,2′-(1,4,8,11-tetraazacyclotetradecane-1,8-diyl) diacetic acid (TE2A); 4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]-hexadecane (CB-TE2A); 3,6,10,13,16,19-hexaazabicyclo[6.6.6]icosane (Sar); phthalocyanines and their derivatives; porphyrins and their derivatives.

16. The molecule claimed in claim 14 , wherein the chelating agent is an acyclic chelator selected from: ethylene-diamine-tetraacetic-acid (EDTA); and diethylene-triamine-penta-acetic acid (DTPA); S-acetylmercaptosuccinic anhydride (SAMSA); (2-mercaptoethyl)(2-((2-mercaptoethyl)amino)ethyl)-carbamic acid (N2S2-DADT); 1,1′-(ethane-1,2-diylbis(azanediyl))bis(2-methylpropane-2-thiol) (N2S2 BAT-TM), (2-(2-mercaptoacetamido)ethyl)-cysteine (N2S2-MAMA); 2,3-bis(2-mercaptoacetamido)-propanoic acid (N2S2 DADS); ethylenedicysteine (EC); 2,2′,2″-nitrilotriethanethiol (NS3); 2-ethylthio-N,N-bis(pyridin-2-yl)methyl-ethanamine (N3S); ((2-mercaptoacetyl)glycylglycyl)carbamic acid (MAG3) and 4-(2-(2-(2-mercaptoacetamido)acetamido)-acetamido)butanoic acid (MAG2-GABA); (1,2-bis{[[6-(carboxy)pyridine-2-yl]methyl]-amino}-ethane) (H2dedpa); Nitrilotris(methylenephosphinic acid) (NTMP); ethylenediaminetetramethylene-phosphonic acid (EDTMP), diethylenetriaminepenta-methylene phosphonic acid (DTPMP); Hydrazinonicotinic acid (HYNIC); N′-{5-[Acetyl(hydroxy)amino]-pentyl}-N-[5-({4-[(5-aminopentyl)-(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxysuccin-amide (Deferoxamine).

17. The molecule claimed in claim 1 , wherein the radionuclide is a radionuclide that may be used for imaging selected from: 99m Tc, 188 Re, 186 Re, 153 Sm, 67 Ga, 68 Ga, 111 In, 59 Fe, 63 Zn, 52 Fe, 45 Ti, 60 Cu, 61 Cu, 67 Cu, 64 Cu, 62 Cu, 198 Au, 199 Au, 195m Pt, 191m Pt, 193m Pt, 117m Sn, 89 Zr, 177 Lu, 16 F, and 123 I.

18. The molecule claimed in claim 1 , wherein the radionuclide is a radionuclide that may be used for therapeutic purposes selected from: 188 Re, 186 Re, 153 Sm, 166 Ho, 90 Y, 89 Sr, 111 In, 153 Gd, 225 Ac, 212 Bi, 213 Bi, 211 At, 60 Cu, 61 Cu, 67 Cu, 64 Cu, 62 Cu, 198 Au, 199 Au, 195m Pt, 193m Pt, 197 Pt, 117m Sn, 103 Pd, 103m Rh, 177 Lu, 223 Ra, 224 Ra, 227 Th, 32 P, 161 Tb and 33 P, 125 I, 203 Pb, 201 Ti, 119 Sb, 58m Co, and 161 Ho.

19. The molecule claimed in claim 1 , wherein the radionuclide is an Auger electron emitting radionuclide.

20. The molecule claimed in claim 19 , wherein the Auger electron emitting radionuclide is selected from 111 In, 203 Pb, 201 Ti, 103 Pd, 103m Rh, 119 Sb, 58m Co, 161 Ho, 161 Tb, 61 Cu, 67 Cu, 195m Pt, 193m Pt, and 117m Sn.

21. The molecule claimed in claim 1 , wherein the chelating agent contains the radionuclide.

22. The molecule as claimed in claim 1 , wherein:
the metabolite that targets tumour cells is a glucose-containing linker that is functionalised for connection to the chelating agent through alkylation or acylation;
the chelating agent is a cyclam functionalised through N-linkages for radioisotope chelation;
the linker is functionalised with maleimide; and
the EPR agent is albumin.

23. The molecule as claimed in claim 22 , further comprising 103 Pd.

24. A method for the synth

Assignees

• The South African Nuclear Energy Corporation Ltd
• Univ Cape Town

Inventors

• Driver Cathryn Helena Stanford
• Zeevaart Jan Rijn
• Parker Mohamed Iqbal
• Hunter Roger

Classifications

• A61K51/0491 Primary

  Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers · CPC title

• A61K51/081

  the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin · CPC title

• A61K51/065

  conjugates with carriers being macromolecules · CPC title

• A61K51/0497 Primary

  conjugates with a carrier being an organic compounds · CPC title

• A61K51/0474

  complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group · CPC title